Repligen Corporation
Repligen Corporation (RGEN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · RGEN · as of Jun 8, 2026
Key Statistics
Explore Repligen Corporation Data
rgen stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 24 · Buy rate: 87.5%
The RGEN analyst consensus is Buy, based on ratings from 24 Wall Street analysts over the past 3 months. The average 12-month price target is $163.14, representing +33.38% upside from the current price of $122.31.
Competitors & Peers
rgen competitorsRGEN
ATR
AVTR
BAX
BIO
CRLStock Performance
Full HistoryAbout Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally…
what is repligen corporation · rgen stock overview · repligen corporation company profile · who is repligen corporation ceo · rgen NASDAQ · repligen corporation headquarters · repligen corporation business segments
About Stock Overview & Key Data
Repligen Corporation (RGEN) is a Healthcare company in the Medical - Instruments & Supplies industry, listed on NASDAQ since Apr 29, 1986. As of the latest trading session, RGEN stock price is $122.31, with a market capitalization of $6.9B. The stock has returned -7.12% over the past 12 months and -25.36% year-to-date.
According to 24 Wall Street analysts, the consensus rating for Repligen Corporation stock is Buy, with an average 12-month price target of $163.14. In fiscal year 2025, Repligen Corporation reported revenue of $738.3M and net income of $48.9M. For detailed data — including Repligen Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Repligen Corporation (RGEN) stock price is $122.31. The stock is traded on NASDAQ under the ticker symbol RGEN. The 52-week range is $100.99 – $175.77.